TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/BLECTED OFFICE (DO/BO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. POTTAXANE COMPOUND, ROTAXANE—BONDED SOLID SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DO/BO/US SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DO/BO/US This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. A copy of the International Application as filed (35 U.S.C. 371(c)) A copy of the International Application as filed (35 U.S.C. 371(c)) Been elected (Article 31). A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Application was filed in the United States Receiving Office (RO/US) A copy of the International Bureau A mendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) A copy of the International Application was filed in the United States Receiving Office (RO/US) A manufactor of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). A mendments to			8, 3, 0									
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE DAILY 5, 2004 PET/RR2004/001651 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE JULY 5, 2003 ITHLE OF INVERVITON ROTAXANE COMPOUND, ROTAXANE—BONDED SOLID SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DO/EO/US Kimoon KIM, et al. Applican herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (3), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a	FORM PTO-1390 U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No.											
INTERNATIONAL APPLICATION NO. PCT/KR2004/001651 INTERNATIONAL FILING DATE JULY 5, 2004 PRIORITY DATE CLAIMED JULY 5, 2003 ITILE OF INVENTION ROTAXANE COMPOUND, ROTAXANE-BONDED SOLID SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DOVEOUS KIMOON KIM, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:	7	TRANSMITTAL LETTER	1751-394									
INTERNATIONAL APPLICATION NO. JULY 5, 2004 PROTEXANE PRIORITY DATE CLAIMED JULY 5, 2003 TITLE OF INVENTION ROTAXANE COMPOUND, ROTAXANE-BONDED SOLID SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DO/DOUS Kimoon KIM, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(b)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. have not been made; however, the time limit for making such amendments has NOT expired. have not been made; however, the time limit for making such amendments has NOT expired. have not been made; however, the time limit for making such amendments has NOT expired. An English language translation of the inventor(s) (35 U.S.C. 371(c)(4)). An english language translation of the inventor(s) (35 U.S.C. 371(c)(4)). An English language												
TITLE OF INVENTION ROTAXANE COMPOUND, ROTAXANE-BONDED SOLID SUBSTRATE, AND BIOCHIP USING THE SAME APPLICANT(S) FOR DOVEOUS Kilmoon KIM, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 3. This is an express request to begin national examination procedures (35 U.S.C. 371(0)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(e)(2)) a. Is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Application as filed (35 U.S.C. 371(e)(2)). a. Is not required, as the application was filed in the United States Receiving Office (RO/US) 6. An English language translation of the International Application as filed (35 U.S.C. 371(e)(2)). a. a are attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(e)(3)). a are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made, however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(e)(3)). 7. An explication Data Sheet under 37 CFR 1.76. An Information Disclosure Statement under 37 CFR 1.79 and 1.98. An English language translation of the amexes to the International Preliminary Examination Report unde				10/563,477								
ROTAXANE COMPOUND, ROTAXANE-BONDED SOLID SUBSTRATE, AND BIOCHTP USING THE SAME APPLICANT(S) FOR DO/BO/US Kimoon KIM, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1.												
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(e)(2)) a		ROTAXANE COMPOUND, RO										
1.												
2.	Applicant	herewith submits to the United Sta	ates Designated/Elected Office (DO/EO/US) the	following items and other information:								
3.	1.	This is a FIRST submission of iter	ns concerning a filing under 35 U.S.C. 371									
(5), (6), (9) and (21) indicated below. 4.	2.	This is a SECOND or SUBSEQU	ENT submission of items concerning a filing un	der 35 U.S.C. 371.								
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US) 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. A power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	3.			I(f)). The submission must include items								
a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US) 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. X	4.	The US has been elected (Article	31).									
a. is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. e. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. X	5. 🗆	 a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. 										
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. 14. A substitute specification (with Preliminary Amendment). A power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 ter. 2 and 35 U.S.C. 1.821-1.825	6.	 is attached hereto. 		C. 371(c)(2)).								
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification (with Preliminary Amendment). 16. A power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired.										
An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). ITEMS 11. TO 20. below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification (with Preliminary Amendment). 16. A power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	8.	An English language translation of	of the amendments to the claims under PCT Arti	cle 19 (35 U.S.C. 371(c)(3)).								
ITEMS 11. TO 20. below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification (with Preliminary Amendment). A power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	9.	An oath or declaration of the inve	entor(s) (35 U.S.C. 371(c)(4)).									
An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification (with Preliminary Amendment). A power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	10.											
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification (with Preliminary Amendment). 16. A power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825	ITEMS 11. TO 20. below concern other document(s) or information included:											
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. Other items or information: [] RO/101 [] RO/105 [] ISA/210(ISR) [] ISA/220 [] ISA/237 [] IB/301 [] IB/304 [] IB/306 [] IB/308 [] IB/332 [] IB/409(IPER) [] IPEA/416 [] Published Application WO 2005/003136 A1	12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification (with Preliminary Amendment). A power of attorney and/or address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825 A second copy of the published international application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). Other items or information:										

U.S. APPLICATIO 10/563		1, see 37 CFR 1.50)	INTERNATIONAL APPLIC PCT/KR2004/001		ATTORNEY DOCKET NO. 1751-394			
The following 21. Basic		\$						
provisions of P	Preliminary 1 CT Article 33	II claims satisfy \$100.00 \$200.00	\$					
23. Search Search fee (37 as an Internatio International S All other situat	CFR 1.445(a) onal Searching earch Report	ion to the USPTO \$100.00 \$400.00 \$500.00	\$					
			TOTAL	OF 21,22 and 23=	\$			
Additional sequence li \$250 for ea	fee for specifi sting or comp ich additional	ication and drawings uter program listing 50 sheets of paper of	filed in paper over 100 sh filed in an electronic medi r a fraction thereof.	eets (excluding um). The fee is	\$			
Total Sheets	Extra Shee	Number of each thereof (round	ch additional 50 or fraction up to a whole number)	RATE				
- 100=	/ 50			X 250.00				
		mishing the oath or d (37 CFR 1.492(e)).	leclaration later than 30 me	onths from the				
Claims		Number Filed	Number Extra	Rate				
Total Claims	_	9-20 =	0	X \$50.00	\$			
Independent C	Claims	2-3=	0	X \$200.00	\$			
Multiple depe	ndent claim(s) (if applicable)		+ \$360.00	\$			
			TOTAL OF ABOVE CA	LCULATIONS =	\$			
	claims small e	າ້	CFR 1.27. The fees indica	ited	\$			
				SUBTOTAL =	\$			
		or furnishing the Eng date (37 CFR 1.492(lish translation later than	30 months from	\$			
- Ino Garnest Cita	incu priority	unic (5 / 01 / 1.172)		ATIONAL FEE =	\$			
			FR 1.21(h)). The assignments of the second o		\$			
	у ша пррторга	ES ENCLOSED =	\$					
					Amount to be refunded	\$		
			charged	\$				
a. A check in the amount of \$								
Barbara Webb Walker Barbara Webb Walker								

fr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/563,477

Applicant : Kimoon KIM et al. Filed : January 5, 2006

TC/A.U. :
Examiner :

Docket No. : 1751-394 Customer No. : 06449 Confirmation No. : 1349

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

Ву

Barbara W. Walker

Attorney for Applicants Registration No. 35,400

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

				Complete if Known		
				Application Number	10/563,477	
	ATION DISC			Filing Date	January 5, 2006	
SIAIEM	ENT BY AP	PLICAN	1	First Named Inventor	Kimoon KIM et al.	
				Group Art Unit		
				Examiner Name		
				Confirmation No.	1349	
Sheet	1	of	2	Attorney Docket Number	1751-394	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docun Number⁴	Nent Kind ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T	
		KR	1020020019325	А	POSCO POSTECH FOUNDATION	03-12-2002	Ab	
		KR	1020030060053	Α	POSTECH FOUNDATION	07-12-2003	Ab	
		KR	1020030024426	А	POSTECH FOUNDATION	03-26-2003	Ab	
		KR	1020030003901	А	POSTECH FOUNDATION	01-14-2003	Ab	
		KR	1020010039662	Α	POSTECH FOUNDATION	05-15-2001	Ab	
							<u> </u>	
		ļ						
· · · · · · · · · · · · · · · · · · ·							<u> </u>	
	-	ļ					_	
	ļ	ļ					<u> </u>	
							1	
	<u></u> _							
Examiner Signature					Date Considered			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Con	nplete if Known	
				Application Number	10/563,477
		Filing Date	January 5, 2006		
STATEME	NT BY API	PLICAI	NT	First Named Inventor	Kimoon KIM et al.
STATEMENT BY APPLICANT		Group Art Unit			
				Examiner Name	
				Confirmation No.	1349
Sheet	2	of	2	Attorney Docket Number	1751-394

	·····	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
		LEVICKY, R., et al., "Using Self-Assembly to Control the Structure of DNA Monolayers on Gold: A Neutron Reflectivity Study", J. Am. Chem. Soc. 1998, 120, pp. 9787-9792					
		PETERSON, A.W., ET AL., "Hybridization of Mismatched or Partially Matched DNA at Surfaces", 11/15/2002, JACS Articles, J. Am. Chem. Soc., 124, 14601-14607					
		HONG, B.J., et al., "Self-Assembly of a Dendron through Multiple Ionic Interaction to Give Mesospacing Between Reactive Amine Groups on the Surface", Langmuir, 2003, 19, pp. 2357-2365					
			i				
Examiner Signature		Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.